Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus.

[PURPOSE] Patients with non-small-cell lung carcinoma (NSCLC) harboring exon 20 insertion (ex20ins) mutations in the epidermal growth factor receptor (EGFR) face a particularly poor prognosis. This consensus aimed to consolidate expert opinions on the diagnosis and management of these patients in view of recent advances in diagnostic and therapeutic approaches.

[METHODS] A comprehensive literature review was conducted to summarize evidence on managing NSCLC patients with ex20ins mutations. Using the Delphi methodology, the perspectives of 30 healthcare professionals (HCPs) from the Spanish National Healthcare System were collected regarding the diagnosis, therapeutic strategies, and patient perspectives of the disease.

[RESULTS] Experts emphasized the critical role of next-generation sequencing (NGS) in diagnosing NSCLC patients, highlighting the need for detailed molecular profiling to optimize therapeutic decisions. Amivantamab was identified as a potential preferred therapeutic option due to its demonstrated benefit in clinical trials, including patients with brain metastases. Additionally, the HCPs underscored the importance of incorporating patient-reported outcomes (PROs) into clinical evaluation and ensuring access to therapies with proven efficacy.

[CONCLUSIONS] This consensus provides a valuable guideline for diagnosing and managing NSCLC patients with ex20ins EGFR mutations, emphasizing the integration of advanced diagnostic tools, evidence-based therapies, and patient-centered care to enhance clinical outcomes and improve patient quality of life.